The European Commission announced on Friday 18 September that they had signed a second contract, this time with Sanofi-GSK, for the purchase of 300 million doses of the Covid-19 vaccine that the pharmaceutical company is developing.
According to the European Commission, the well-established technique that is used — combining a protein-based antigen with an adjuvant — improves the likelihood of delivering an effective vaccine that can be manufactured on a large scale. Sanofi-GSK expects...